• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic.
【24h】

Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic.

机译：Tigecycline：一流的糖基环素抗生素的临床前和临床研究综述。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tigecycline is a novel glycylcycline antibacterial agent discovered and developed by Wyeth Research. The U.S. Food and Drug Administration (FDA) recently approved the agent for use in patients with complicated skin infections, skin-structure infections and intra-abdominal infections. Tigecycline is currently under review by regulatory agencies worldwide. Global clinical trials are underway to further assess the efficacy of tigecycline for community- and hospital- acquired pneumonia. Because of the expanded broad spectrum of activity of tigecycline with proven utility against Gram-positive, Gram-negative, anaerobic and atypical pathogens in addition to resistant organisms of clinical importance--community- and hospital-acquired methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., penicillin-resistant Streptococcus pneumoniae and Escherichia coli and Klebsiella pneumoniae expressing extended-spectrum beta-lactamases--this novel antibiotic has come into clinical use at a critical time and will be a welcome asset to the current armamentarium.
机译：Tigecycline是Wyeth Research发现和开发的新型糖基环素抗菌剂。美国食品药品监督管理局（FDA）最近批准了该药物用于患有复杂皮肤感染，皮肤结构感染和腹腔内感染的患者。目前，全球监管机构正在审查Tigecycline。全球临床试验正在进行中，以进一步评估替加环素对社区和医院获得性肺炎的疗效。由于替加环素具有广泛的活性，除了对临床具有重要意义的耐药菌（社区和医院获得的耐甲氧西林的金黄色葡萄球菌，万古霉素-）外，还具有对革兰氏阳性，革兰氏阴性，厌氧和非典型病原体的有效效用耐药的肠球菌属，耐青霉素的肺炎链球菌，大肠杆菌和肺炎克雷伯氏菌均表达广谱β-内酰胺酶，这种新型抗生素已在关键时刻投入临床使用，将成为当前武器库中的受欢迎资产。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号